Expert Review of Neurotherapeutics最新文献_第5页

UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder. 英国医用大麻登记处：对开具大麻精油和干花治疗广泛性焦虑症的患者进行的队列研究。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-11-11 DOI: 10.1080/14737175.2024.2423634

John Warner-Levy, Simon Erridge, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Karl Bexley, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder.","authors":"John Warner-Levy, Simon Erridge, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Karl Bexley, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren","doi":"10.1080/14737175.2024.2423634","DOIUrl":"10.1080/14737175.2024.2423634","url":null,"abstract":"Background: Generalized anxiety disorder (GAD) is a common mental health condition. The endocannabinoid system has become a focus for new therapies, increasing interest in cannabis-based medicinal products (CBMPs). This study uses data from the UK Medical Cannabis Registry (UKMCR) to investigate real-world outcomes and safety of different CBMP formulations in GAD patients.Methods: This study analyzed patient-reported outcomes from 302 GAD patients prescribed CBMPs (oil-based, dried flower, or a combination). Anxiety (GAD-7), sleep quality (SQS), and quality of life (EQ-5D-5 L) were assessed at 1, 3, 6, and 12 months. Adverse events were recorded.Results: All CBMP formulations were associated with improvements in anxiety, sleep, and quality of life over 12 months (p < 0.050). At 12 months, there were no significant differences in outcomes between formulations (p > 0.050). The majority of reported adverse events (n = 707) were mild (n = 343) or moderate (n = 285) in severity, with no life-threatening events observed.Conclusion: This study provides real-world evidence supporting the potential of CBMPs for improving GAD symptoms. Patients prescribed both oil-based and dried flower formulations have similar outcomes over 12 months. Further research is needed to determine the optimal CBMP formulation and long-term effects.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1193-1202"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal zavegepant for the acute treatment of migraine. 用于偏头痛急性期治疗的zavegepant气雾剂。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1080/14737175.2024.2405741

Guy Greco, Teshamae Monteith

{"title":"Intranasal zavegepant for the acute treatment of migraine.","authors":"Guy Greco, Teshamae Monteith","doi":"10.1080/14737175.2024.2405741","DOIUrl":"10.1080/14737175.2024.2405741","url":null,"abstract":"Introduction: Migraine is a highly prevalent chronic, inherited neurological condition of the brain which carries a significant level of disability. Despite advances, there is an unmet need for more effective therapies.Areas covered: Zavegepant nasal spray is a recent therapeutic option which acts as a calcitonin gene-related peptide receptor antagonist. The objective is to review the efficacy, safety, and additional results of the most recent trials investigating intranasal zavegepant for the acute treatment of migraine with or without aura. The authors searched PubMed using the keywords 'zavegepant,' 'Zavzpret,' 'migraine,' 'calcitonin gene-related peptide,' 'CGRP receptor antagonists.' This article covers Phase 1, Phase 2/3, and Phase 3 randomized, double-blind, placebo-controlled trials to evaluate the efficacy of intranasal zavegepant for treatment of acute migraine attacks.Expert opinion: Intranasal zavegepant is an efficacious, safe, and tolerable anti-migraine drug based on clinical trials and clinical experience. It is especially useful for patients who experience attacks of sudden onset, those with nausea or vomiting, or a high cardiovascular risk burden. Dysgeusia was common; future studies are needed to better characterize this adverse event. Head-to-head studies are lacking with other migraine-specific therapies; the decision to treat should be patient-centered, with attack-specific characteristics in mind.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1131-1140"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Behavioural Therapy for tic disorders: a comprehensive review of the literature. 治疗抽搐症的行为疗法：文献综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-09-22 DOI: 10.1080/14737175.2024.2405740

Simon Morand-Beaulieu, Natalia Szejko, Julian Fletcher, Tamara Pringsheim

{"title":"Behavioural Therapy for tic disorders: a comprehensive review of the literature.","authors":"Simon Morand-Beaulieu, Natalia Szejko, Julian Fletcher, Tamara Pringsheim","doi":"10.1080/14737175.2024.2405740","DOIUrl":"10.1080/14737175.2024.2405740","url":null,"abstract":"Introduction: Behavioral therapies are recommended as a first-line intervention for Tourette syndrome and persistent motor or phonic tic disorder.Areas covered: In this review, the authors summarize randomized controlled trials on the comprehensive behavioral intervention for tics (CBIT), habit reversal therapy (HRT), and exposure and response prevention (ERP). Studies of face-to-face treatment, treatment by video conferencing, group treatment, and internet delivered treatment were assessed, as well as evidence of treatment predictors, modifiers, and mediators.Expert opinion: There is high-quality evidence for face-to-face one-on-one treatment with CBIT, and data suggesting that one-on-one treatment by videoconference provides similar benefit. Limited data on group treatment with CBIT/HRT suggests inferiority to individual treatment, while internet-based CBIT programs appear more beneficial than wait list or psychoeducation. There is one face-to-face one-on-one treatment comparison of ERP to HRT, suggesting equal benefit. Internet-based ERP with minimal therapist support appears effective, although effect sizes are small. One study using behavioral therapy with ERP or HRT found similar benefit to medical treatment with antipsychotics. Data on predictors, modifiers, and mediators of treatment efficacy are emerging. In summary, behavioral therapies are an important treatment modality for tic disorders. Furthermore, important efforts to improve treatment accessibility are underway.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1181-1191"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the current and emerging treatment options for vestibular migraine. 前庭性偏头痛的现有和新兴治疗方案概览。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1080/14737175.2024.2405739

Elena P Calandre, Christine Bassila, Mahmoud Slim, Fernando Rico-Villademoros

{"title":"An overview of the current and emerging treatment options for vestibular migraine.","authors":"Elena P Calandre, Christine Bassila, Mahmoud Slim, Fernando Rico-Villademoros","doi":"10.1080/14737175.2024.2405739","DOIUrl":"10.1080/14737175.2024.2405739","url":null,"abstract":"Introduction: Vestibular migraine is a relatively common syndrome characterized by the occurrence of vertigo and other vestibular symptoms, frequently -but not always- accompanied by migraine symptoms, such as headache, photophobia, and phonophobia.Areas covered: The authors review the acute or abortive treatment during an attack and prophylactic treatment of vestibular migraines, including pharmacological and non-pharmacological options.Expert opinion: Since its recognition as an independent clinical entity is recent, studies concerning its different treatment alternatives are still scarce, and the level of evidence of published studies is generally low. For acute treatment, although available data are conflicting, triptans are usually tried first. Neurostimulating devices can also be considered for acute treatment of vestibular migraine. Regarding the preventive treatment of vestibular migraine, based on the results of two randomized clinical trials and its pharmacological properties, flunarizine should be considered as the first treatment option. Second-line preventive treatments encompass propranolol, topiramate, venlafaxine, and valproic acid. Among non-pharmacological options, vestibular rehabilitation seems to be a sound prophylactic treatment option.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1157-1179"},"PeriodicalIF":3.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can pharmacotherapy help to reduce trichotillomania? 药物疗法有助于减轻毛发躁动症吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2398471

Michael Thomson, Verinder Sharma

引用次数: 0

Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry. 更年期及其对氟马尼珠单抗预防偏头痛疗效的影响：对希腊前瞻性真实世界登记的事后分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-16 DOI: 10.1080/14737175.2024.2403576

Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis

{"title":"Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.","authors":"Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis","doi":"10.1080/14737175.2024.2403576","DOIUrl":"10.1080/14737175.2024.2403576","url":null,"abstract":"Objective: This post-hoc analysis of data extracted from a prospective study aimed to explore for the first time if the efficacy of fremanezumab in preventing difficult-to-treat migraine, according to ICHD-III, would differ between pre-menopausal and post-menopausal women.Methods: A total of 171 (aged 18-70 years) fremanezumab-treated female migraine patients for six consecutive months were classified to those at pre-menopausal (n = 82) or post-menopausal (n = 89). Monthly headache days (MHD), disability, and quality of life (QOL) outcomes were assessed at baseline and at week 24 post-fremanezumab within subgroups and were then compared between them. Safety and tolerability were also assessed.Results: In both groups, fremanezumab demonstrated significant reductions in MHDs, reduced disability, and higher QOL scores at week 24 post-treatment, compared to baseline. However, the between-subgroup comparison documented that pre-menopausal women and those at post-menopausal comparably benefited with significant reductions in overall MHDs (p = 0.883). Less disability, according to MIDAS (p = 0.696) and HIT-6 scores (p = 0.912), as well as higher QOL scores at week 24 post-fremanezumab, were also comparably evident in both groups. Safety was excellent across both subgroups.Conclusion: Fremanezumab can be considered a very effective treatment option for preventing migraines in difficult-to-treat women, aged 18-70 years, regardless of their menopausal status.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1119-1126"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The major challenges with pharmacologic management of chronic traumatic encephalopathy. 慢性创伤性脑病药物治疗的主要挑战。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-08-04 DOI: 10.1080/14737175.2024.2387264

Brendan P Campbell, Katherine W Turk, Andrew E Budson

引用次数: 0

Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature. 阿尔茨海默病鉴别诊断中的脑脊液：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2400683

Tina Milos, Barbara Vuic, Nikola Balic, Vladimir Farkas, Gordana Nedic Erjavec, Dubravka Svob Strac, Matea Nikolac Perkovic, Nela Pivac

{"title":"Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature.","authors":"Tina Milos, Barbara Vuic, Nikola Balic, Vladimir Farkas, Gordana Nedic Erjavec, Dubravka Svob Strac, Matea Nikolac Perkovic, Nela Pivac","doi":"10.1080/14737175.2024.2400683","DOIUrl":"10.1080/14737175.2024.2400683","url":null,"abstract":"Introduction: The importance of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) diagnosis is rapidly increasing, and there is a growing interest in the use of CSF biomarkers in monitoring the response to therapy, especially in the light of newly available approaches to the therapy of neurodegenerative diseases.Areas covered: In this review we discuss the most relevant measures of neurodegeneration that are being used to distinguish patients with AD from healthy controls and individuals with mild cognitive impairment, in order to provide an overview of the latest information available in the scientific literature. We focus on markers related to amyloid processing, markers associated with neurofibrillary tangles, neuroinflammation, neuroaxonal injury and degeneration, synaptic loss and dysfunction, and markers of α-synuclein pathology.Expert opinion: In addition to neuropsychological evaluation, core CSF biomarkers (Aβ42, t-tau, and p-tau181) have been recommended for improvement of timely, accurate and differential diagnosis of AD, as well as to assess the risk and rate of disease progression. In addition to the core CSF biomarkers, various other markers related to synaptic dysfunction, neuroinflammation, and glial activation (neurogranin, SNAP-25, Nfl, YKL-40, TREM2) are now investigated and have yet to be validated for future potential clinical use in AD diagnosis.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1063-1079"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brain atrophy assessment in multiple sclerosis: technical- and subject-related barriers for translation to real-world application in individual subjects. 多发性硬化症的脑萎缩评估：将技术和受试者相关障碍转化为个体受试者的实际应用。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2398484

Robert Zivadinov, Ashley Tranquille, Jack A Reeves, Michael G Dwyer, Niels Bergsland

{"title":"Brain atrophy assessment in multiple sclerosis: technical- and subject-related barriers for translation to real-world application in individual subjects.","authors":"Robert Zivadinov, Ashley Tranquille, Jack A Reeves, Michael G Dwyer, Niels Bergsland","doi":"10.1080/14737175.2024.2398484","DOIUrl":"10.1080/14737175.2024.2398484","url":null,"abstract":"Introduction: Brain atrophy is a well-established MRI outcome for predicting clinical progression and monitoring treatment response in persons with multiple sclerosis (pwMS) at the group level. Despite the important progress made, the translation of brain atrophy assessment into clinical practice faces several challenges.Areas covered: In this review, the authors discuss technical- and subject-related barriers for implementing brain atrophy assessment as part of the clinical routine at the individual level. Substantial progress has been made to understand and mitigate technical barriers behind MRI acquisition. Numerous research and commercial segmentation techniques for volume estimation are available and technically validated, but their clinical value has not been fully established. A systematic assessment of subject-related barriers, which include genetic, environmental, biological, lifestyle, comorbidity, and aging confounders, is critical for the interpretation of brain atrophy measures at the individual subject level. Educating both medical providers and pwMS will help better clarify the benefits and limitations of assessing brain atrophy for disease monitoring and prognosis.Expert opinion: Integrating brain atrophy assessment into clinical practice for pwMS requires overcoming technical and subject-related challenges. Advances in MRI standardization, artificial intelligence, and clinician education will facilitate this process, improving disease management and potentially reducing long-term healthcare costs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1081-1096"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review. 抗癫痫药物与智障和癫痫老年人的挑战行为之间的关系：综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-08-19 DOI: 10.1080/14737175.2024.2393322

Seungyoun Moon, Lance Watkins, Maire O'Dwyer, Rohit Shankar

{"title":"Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review.","authors":"Seungyoun Moon, Lance Watkins, Maire O'Dwyer, Rohit Shankar","doi":"10.1080/14737175.2024.2393322","DOIUrl":"10.1080/14737175.2024.2393322","url":null,"abstract":"Introduction: There is increased focus on the negative impact of the overprescribing of medication, specifically psychotropic medication, including anti-seizure medications (ASM), in people with Intellectual Disability (ID). This is particularly important for the older adult population, where multi-morbidity and polypharmacy are more common. ASMs are associated with psychiatric and behavioral adverse effects. Furthermore, there is growing awareness of the anticholinergic burden for older adults with epilepsy and ID and the relationship with behaviors that challenge (BtC).Areas covered: This review defines the older adult population and outlines the relationship between epilepsy and ID. BtC is outlined in the context of the population and the relationship with ASMs. The evidence base to guide prescribing and de-prescribing for newer ASMs is also presented, including pragmatic data.Expert opinion: Polypharmacy, particularly psychotropics, are a mortality risk factor for older adults with epilepsy and ID. Therefore, any BtC requires a holistic assessment with a multi-disciplinary approach. This includes specific consideration of all prescribed medicines in the context of polypharmacy. There should be routine reviews, at least annually, for those aged 40 years and over particularly focused on anticholinergic burden and/or polypharmacy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1097-1105"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0